Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind, placebo-controlled phase 2 trial of GSK3389404 in chronic hepatitis B
jRCT2080223861Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2018
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing GSK3389404 with Placebo (2 arms). Primary endpoints: Safety and tolerability of GSK3389404, Pharmacokinetics of GSK3389404 and 1 more. Started Apr 2018; status: completed.
02
Drugs
GSK3389404
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on jRCT2080223861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223861.